Astellas, Seattle Genetics Break Ground With US ADC Approval

Earlier-Stage Combo Also Shows Big Promise

Co-developers gain nod for novel antibody-drug conjugate that provides new option for patients with advanced form of bladder cancer.

Bladder cancer
ADC Provides New Option For Advanced Bladder Cancer • Source: Shutterstock

The US Food and Drug Administration (FDA) has granted accelerated approval to Astellas Pharma Inc. and Seattle Genetics Inc.'s first-in-class antibody-drug conjugate (ADC) Padcev (enfortumab vedotin-ejfv), providing a new treatment option for later-stage patients with a form of cancer that can currently be very difficult to treat.

The novel therapy, which targets the nectin-4 cell surface protein highly expressed in bladder cancer, has been cleared for the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category